Nyxoah SA NYXH 深 滬
已收盤 02-06 16:00:00 美东时间
4.65
+0.060
+1.31%
華盛通- 最 高4.72
- 今 開4.68
- 成交量 1.00万股
- 最 低 4.60
- 昨 收 4.59
- 總市值 2.00亿
- 52周最高 11.87
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 4.345
- 委 比 -73.61%
- 總股本 4302.65万
- 歷史最高 37.00
- 量 比 0.32
- 振 幅 2.61%
- 歷史最低 4.00
- 每 手 1
- 風險率 1.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
Stifel Maintains Buy on Nyxoah, Lowers Price Target to $11
Stifel analyst Jonathan Block maintains Nyxoah (NASDAQ:NYXH) with a Buy and lowers the price target from $12 to $11.
01-29 23:50
Nyxoah SA Expands Its Manufacturing Footprint In Wallonia; Co. Signs An Agreement With Légiapark To Support Nyxoah's Product Development Activities And The Creation Of A Nearly 2,000 Square Meter Manufacturing Facility
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today
01-22 05:11
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth
Nyxoah expands its Belgian manufacturing capacity to support global growth, including a new 2,000 sqm facility with a state-of-the-art cleanroom, in collaboration with LégiaPark and ABN Cleanroom Technology, to meet increasing demand and strengthen partnerships in the Belgian life sciences ecosystem. (186 characters)
01-21 21:05
Nyxoah reports Preliminary Q4 results
Nyxoah press release (NYXH): Q4 gross revenue is expected to be approximately €6.3 million As of December 31, 2025, cash, cash equivalents and financial assets are expected to be approximately €47.9 ...
01-13 05:12
Nyxoah Expects Q4 Net Revenue Of €5.7M, FY25 Net Revenue Of ~€10M
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today
01-13 05:07
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026
Nyxoah reported strong preliminary financial results for Q4 2025, with net revenue of €5.7 million, up 348% year-over-year. Full year 2025 net revenue reached €10 million, a 122% increase from 2024. U.S. commercialization contributed significantly to growth, with 145 surgeons trained and 57 activated accounts. Cash reserves stood at €47.9 million. The company expects U.S. net revenue to grow 25% in Q1 2026 and will present at the J.P. Morgan Heal...
01-12 21:05
Publication relating to transparency notification
On January 12, 2026, Nyxoah SA announced receipt of a transparency notification from BNP Paribas Asset Management SA. As of December 31, 2025, BNP Paribas Asset Management Europe SAS holds 1,409,791 voting rights, representing 3.28% of the total 43,026,460 voting rights. This notification was triggered by the merger between BNP Paribas Asset Management Europe SAS and AXA Investment Managers SA, which resulted in crossing the 3% threshold.
01-12 06:00
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $9
Piper Sandler analyst Adam Maeder reiterates Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $12 to $9.
2025-11-15 00:15
